Document Type
Article
Publication Date
4-25-2022
Abstract
The coronavirus disease 2019 (COVID-19) pandemic requires urgent implementation of effective community-engaged strategies to enhance education, awareness, and inclusion of underserved communities in prevention, mitigation, and treatment efforts. The Texas Community-Engagement Alliance Consortium was established with support from the United States’ National Institutes of Health (NIH) to conduct community-engaged projects in selected geographic locations with a high proportion of medically underserved minority groups with a disproportionate burden of COVID-19 disease and hospitalizations. The purpose of this paper is to describe the development of the Consortium. The Consortium organized seven projects with focused activities to address COVID-19 clinical and vaccine trials in highly affected counties, as well as critical statewide efforts. Five Texas counties (Bexar, Dallas, Harris, Hidalgo, and Tarrant) were chosen by NIH because of high concentrations of underserved minority communities, existing community infrastructure, ongoing efforts against COVID-19, and disproportionate burden of COVID-19. Policies and practices can contribute to disparities in COVID-19 risk, morbidity, and mortality. Community engagement is an essential element for effective public health strategies in medically underserved minority areas. Working with partners, the Consortium will use community engagement strategies to address COVID-19 disparities.
Recommended Citation
Seguin-Fowler, R., Amos, C., Beech, B., Ferrer, R., McNeill, L., Opusunju, J., . . . Vishwanatha, J. (2022). The Texas Community-Engagement Research Alliance Against COVID-19 in Disproportionately Affected Communities (TX CEAL) Consortium. Journal of Clinical and Translational Science, 6(1), E64. doi:10.1017/cts.2022.395
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
DOI
10.1017/cts.2022.395
Comments
© The Author(s), 2022. Published by Cambridge University Press on behalf of The Association for Clinical and Translational Science